BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45. [PMID: 25343125 DOI: 10.5582/irdr.2014.01001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
2 Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J 2019;17:10. [PMID: 31160889 DOI: 10.1186/s12959-019-0198-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 19.3] [Reference Citation Analysis]
3 Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae–associated hemolytic uremic syndrome. Pediatr Nephrol 2020;35:1585-91. [DOI: 10.1007/s00467-019-04342-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
4 Smith-Jackson K, Marchbank KJ. Targeting properdin in the treatment of atypical haemolytic uraemic syndrome: better than eculizumab? Ann Transl Med 2018;6:S62. [PMID: 30613637 DOI: 10.21037/atm.2018.10.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
5 Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Pediatr Drugs 2016;18:413-20. [DOI: 10.1007/s40272-016-0194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Åkesson A, Zetterberg E, Klintman J. At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature: At the Cross Section of TMA and aHUS. Ther Apher Dial 2017;21:304-19. [DOI: 10.1111/1744-9987.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
7 Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Kidney Int 2019;96:67-79. [PMID: 30910380 DOI: 10.1016/j.kint.2019.01.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
8 Triebwasser MP, Wu X, Bertram P, Hourcade DE, Nelson DM, Atkinson JP. Timing and mechanism of conceptus demise in a complement regulatory membrane protein deficient mouse. Am J Reprod Immunol 2018;80:e12997. [PMID: 29924462 DOI: 10.1111/aji.12997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ma M, Mazumder S, Kwak H, Adams M, Gregory M. Case Report: Acute Thrombotic Microangiopathy in a Patient with STING-Associated Vasculopathy with Onset in Infancy (SAVI). J Clin Immunol 2020;40:1111-5. [PMID: 32860170 DOI: 10.1007/s10875-020-00850-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep 2019;4:1568-76. [PMID: 31890998 DOI: 10.1016/j.ekir.2019.07.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
11 Chand DH, Zaidman C, Arya K, Millner R, Farrar MA, Mackie FE, Goedeker NL, Dharnidharka VR, Dandamudi R, Reyna SP. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series. The Journal of Pediatrics 2021;231:265-8. [DOI: 10.1016/j.jpeds.2020.11.054] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
12 Vakiti A, Singh D, Pilla R, Alhaj-Moustafa M, Fitzpatrick KW. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. J Oncol Pharm Pract. 2019;25:1011-1015. [PMID: 29768958 DOI: 10.1177/1078155218774895] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clin Epidemiol. 2020;12:295-305. [PMID: 32210633 DOI: 10.2147/clep.s245642] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
14 Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3:CD012862. [PMID: 33783815 DOI: 10.1002/14651858.CD012862.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Nanjappa S, Singh V, Uttamchandani S, Pabbathi S. Thrombotic Microangiopathy in a Patient Treated With Gemcitabine. Cancer Control 2017;24:54-6. [PMID: 28178713 DOI: 10.1177/107327481702400108] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Jin A, Boroujerdi-Rad L, Shah G, Chen JL. Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab. Clin Kidney J 2016;9:576-9. [PMID: 27478600 DOI: 10.1093/ckj/sfw035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Discipio RG, Schraufstatter IU. Magnetic bead based assays for complement component C5. Journal of Immunological Methods 2017;450:50-7. [DOI: 10.1016/j.jim.2017.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Ueda Y, Mohammed I, Song D, Gullipalli D, Zhou L, Sato S, Wang Y, Gupta S, Cheng Z, Wang H, Bao J, Mao Y, Brass L, Zheng XL, Miwa T, Palmer M, Dunaief J, Song WC. Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood 2017;129:1184-96. [PMID: 28057640 DOI: 10.1182/blood-2016-07-728253] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
19 Alge JL, Wenderfer SE, Hicks J, Bekheirnia MR, Schady DA, Kain JS, Braun MC. Hemolytic uremic syndrome as the presenting manifestation of WT1 mutation and Denys-Drash syndrome: a case report. BMC Nephrol 2017;18:243. [PMID: 28720077 DOI: 10.1186/s12882-017-0643-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Singh P, Chen H, Gordon CE, Ghai S, Sloan JM, Quillen K, Moradi S, Chitalia V, Gautam A, Henderson J, Francis JM. Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation. Kidney Med 2019;1:139-43. [PMID: 32734194 DOI: 10.1016/j.xkme.2019.03.005] [Reference Citation Analysis]
21 Horiuchi T, Tsukamoto H. Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Inflamm Regen 2016;36:11. [PMID: 29259684 DOI: 10.1186/s41232-016-0013-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
22 Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 2020;21:245. [PMID: 32605540 DOI: 10.1186/s12882-020-01888-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
23 Edens C, Rodrigues BC, Lacerda MI, Dos Santos FC, De Jesús GR, De Jesús NR, Levy RA, Leatherwood C, Mandel J, Bermas B. Challenging cases in rheumatic pregnancies. Rheumatology (Oxford) 2018;57:v18-25. [PMID: 30137591 DOI: 10.1093/rheumatology/key172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Kaartinen K, Safa A, Kotha S, Ratti G, Meri S. Complement dysregulation in glomerulonephritis. Semin Immunol 2019;45:101331. [PMID: 31711769 DOI: 10.1016/j.smim.2019.101331] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
25 Bowen EE, Coward RJ. Advances in our understanding of the pathogenesis of hemolytic uremic syndromes. Am J Physiol Renal Physiol. 2018;314:F454-F461. [PMID: 29167171 DOI: 10.1152/ajprenal.00376.2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Bajwa R, DePalma JA, Khan T, Cheema A, Kalathil SA, Hossain MA, Haroon A, Madhurima A, Zheng M, Nayer A, Asif A. C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. Case Rep Nephrol Dial 2018;8:25-34. [PMID: 29594148 DOI: 10.1159/000486848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Gioco R, Corona D, Ekser B, Puzzo L, Inserra G, Pinto F, Schipa C, Privitera F, Veroux P, Veroux M. Gastrointestinal complications after kidney transplantation. World J Gastroenterol 2020; 26(38): 5797-5811 [PMID: 33132635 DOI: 10.3748/wjg.v26.i38.5797] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
28 Robertson JJ, Brem E, Koyfman A. The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management. The Journal of Emergency Medicine 2017;53:202-11. [DOI: 10.1016/j.jemermed.2017.02.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Gebregeorgis W, Patel I, Thakur M, Bhutani D, Woldie I. Collapsing glomerulopathy associated with hemophagocytic syndrome in a patient with NK/T cell lymphoma. Clin Nephrol Case Stud 2016;4:11-7. [PMID: 29043136 DOI: 10.5414/CNCS108586] [Reference Citation Analysis]
30 Kozlovskaya NL, Chebotareva NV, Nikogosova AD, Demyanova KA, Varshavsky VA, Roshchupkina SV. [Incomplete thrombotic microangiopathy as a variant of hemolytic-uremic syndrome]. Ter Arkh 2016;88:77-9. [PMID: 27296266 DOI: 10.17116/terarkh201688677-79] [Reference Citation Analysis]
31 Witte D, Hartmann H, Drube J, Haffner D, Illsinger S. [Thrombotic Microangiopathy (TMA) after Gene Replacemant Therapy (GRT) due to Spinal Muscular Atrophy: Case Summary and Recommendations for Treatment]. Klin Padiatr 2021. [PMID: 34388834 DOI: 10.1055/a-1538-4936] [Reference Citation Analysis]